Tumor Ablation Market - Global Forecast to 2029
| 出版 | MarketsandMarkets |
| 出版年月 | 2024年5月 |
| ページ数 | 192 |
| 図表数 | 202 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global tumor ablation market is projected to reach USD 1.4 billion by 2029 from USD 0.8 billion in 2024, at a CAGR of 10.0% from 2024 to 2029. Aging population, coupled with a rise in tumor cases such as osteoid osteoma, has increased the demand for these products. Moreover, increased awareness of ablation procedures over conventional procedures has driven demand for tumor ablation systems.
“The radiofrequency ablation segment of technology segment held the largest share of the market in 2023”
The tumor ablation market is segmented based on technology into radiofrequency ablation, microwave ablation, laser ablation, high-intensity focused ultrasound (HIFU), cryoablation, and irreversible electroporation (IRE). As the global population ages, conditions affecting the major organs are more prevalent, contributing to the demand for supportive and rehabilitative solutions. Additionally, advancements in technology have led to the development and incorporation of ablation systems, expanding the market further.
“The generators segment is projected to register the highest CAGR during the forecast period.”
Based on product type, the tumor ablation market is segmented into generators and probes/electrodes. The generators segment accounted for the largest market share in 2023. The probes/electrodes market is witnessing growth due to recent regulatory approvals of ablation systems and favourable reimbursement policies. The probes/electrodes have undergone certain technological advancements supporting the precise ablation procedure. The growing awareness of the importance of early detection and the shift towards value-based healthcare has also contributed to the increasing demand for soft and elastic braces and its growing market.
“The laparoscopic ablation segment for mode of treatment segment is projected to register a significant CAGR during the forecast period.”
Based on mode of treatment, the tumor ablation market is segmented into surgical ablation, laparoscopic ablation, and percutaneous ablation . The surgical ablation segment accounted for the largest market share in 2023. Growing investments in R&D and rising demand for less invasive alternative is driving the growth of this segment.
“The liver cancer segment for application segment held held the largest share of the market in 2022”.
Based on application, the tumor ablation market is segmented into liver cancer, lung cancer, bone cancer, kidney cancer, and other applications. The liver cancer was the major segment, accounted for the largest share of the tumor ablation market in 2023. Rising cancer incidence is supported by the increasing aging population. This ultimately drives the adoption of tumor ablation systems. A rising number of campaigns for the early detection of symptoms is also contributing to the increasing utilization of ablation treatment in end-user facilities.
“The cancer care center segment for the end user segment is projected to register a significant CAGR during the forecast period.”
The tumor ablation market is segmented by end user into hospitals and clinics, cancer care centers, and ambulatory surgery centers. The hospitals and clinics segment accounted for a significant market share in 2023. The emphasis on non- and minimally invasive treatment among the geriatric population helps the growing preference for ablation treatment solutions, driving the integration of tumor ablation systems into hospital settings.
“The market in the North America region is expected to witness the highest growth during the forecast period.”
The North America tumor ablation market is expected to hold a major share during the forecast period. The US market holds a dominating position in the North American market, primarily due to the region’s high healthcare spending, rising prevalence of target diseases, a growing number of non-invasive treatments, and technological advancements in ablation systems.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–30%, Tier 2–42%, and Tier 3– 28%
• By Designation: Director-level–10%, C-level–14%, and Others–76%
• By Region: North America–40%, Europe–30%, Asia Pacific–22%, Latin America–6%, and the Middle East & Africa–2%
The prominent players in the tumor ablation market are Medtronic Plc (Ireland), Johnson & Johnson MedTech (US), Stryker Corporation (US), Varian Medical Systems, Inc. (US), AngioDynamics, Inc. (US), Boston Scientific Corporation (US) among others.
Research Coverage
This report studies the tumor ablation market based on technology, product type, mode of treatment, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall tumor ablation market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.
This report provides insights on the following pointers:
• Analysis of key drivers (increasing cancer incidence and rising geriatric population, rising focus on minimally invasive procedures, technological advancements in the field of tumor ablation, rising number of awareness campaigns and early detection), restraints (high cost of tumor ablation systems, unfavorable reimbursement scenario), opportunities (rising healthcare expenditure across emerging countries, increasing number of hospitals), and challenges (rising adoption of refurbished tumor ablation systems, hospital budget cuts) influencing the growth of the tumor ablation market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the tumor ablation market
• Market Development: Comprehensive information about lucrative markets–the report analyses the tumor ablation market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tumor ablation market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players – such as Johnson & Johnson (US), Medtronic Plc (Ireland), Stryker Corporation (US), Varian Medical Systems, Inc. (US), Olympus (Japan), AngioDynamics, Inc. (US), Boston Scientific Corporation (US) among others.
Table of Contents
1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS & EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
1.3.2 YEARS CONSIDERED 28
1.3.3 CURRENCY CONSIDERED 29
1.4 RESEARCH LIMITATIONS 29
1.5 KEY STAKEHOLDERS 29
1.6 SUMMARY OF CHANGES 30
1.7 RECESSION IMPACT 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
FIGURE 1 RESEARCH DESIGN 31
2.1.1 SECONDARY RESEARCH 32
2.1.2 PRIMARY RESEARCH 33
2.1.2.1 Primary sources 33
2.1.2.2 Key industry insights 34
2.1.2.3 Breakdown of primaries 34
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 34
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35
2.2 MARKET SIZE ESTIMATION 35
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36
2.2.1 BOTTOM-UP APPROACH 37
2.2.1.1 Approach 1: Company revenue estimation approach 37
FIGURE 5 TUMOR ABLATION MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION) 37
2.2.1.2 Approach 2: Customer-based market estimation 38
FIGURE 6 TUMOR ABLATION MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 38
2.2.1.3 Growth forecast 39
2.2.1.4 CAGR projections 39
FIGURE 7 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS 39
2.3 DATA VALIDATION APPROACH 40
FIGURE 8 DATA TRIANGULATION METHODOLOGY 40
2.4 MARKET SHARE ASSESSMENT 41
2.5 STUDY ASSUMPTIONS 41
2.6 GROWTH RATE ASSUMPTIONS 41
2.7 RISK ASSESSMENT 42
2.8 RECESSION IMPACT ANALYSIS 42
3 EXECUTIVE SUMMARY 43
FIGURE 9 TUMOR ABLATION MARKET, TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 43
FIGURE 10 TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024 VS. 2029 (USD MILLION) 44
FIGURE 11 TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2024 VS. 2029 (USD MILLION) 44
FIGURE 12 TUMOR ABLATION MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 45
FIGURE 13 TUMOR ABLATION MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 45
FIGURE 14 TUMOR ABLATION MARKET: GEOGRAPHIC SNAPSHOT 46
4 PREMIUM INSIGHTS 47
4.1 TUMOR ABLATION MARKET OVERVIEW 47
FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH 47
4.2 NORTH AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY 47
FIGURE 16 MICROWAVE ABLATION SEGMENT TO REGISTER SIGNIFICANT GROWTH IN NORTH AMERICA DURING FORECAST PERIOD 47
4.3 EUROPE: TUMOR ABLATION MARKET, BY APPLICATION 48
FIGURE 17 LIVER CANCER SEGMENT TO DOMINATE MARKET IN EUROPE DURING FORECAST PERIOD 48
4.4 ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER 48
FIGURE 18 HOSPITALS & CLINICS SEGMENT TO CONTINUE TO HOLD LARGEST SHARE IN ASIA PACIFIC MARKET 48
4.5 GEOGRAPHIC SNAPSHOT OF TUMOR ABLATION MARKET 49
FIGURE 19 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
FIGURE 20 TUMOR ABLATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
5.2.1 DRIVERS 51
5.2.1.1 Increasing cancer incidence and rising geriatric population 51
5.2.1.2 Rising focus on minimally invasive procedures 51
5.2.1.3 Technological advancements in field of tumor ablation 51
5.2.1.4 Rising number of awareness campaigns and early detection 52
5.2.2 RESTRAINTS 52
5.2.2.1 High cost of tumor ablation systems 52
5.2.2.2 Unfavorable regulatory scenario 53
5.2.3 OPPORTUNITIES 53
5.2.3.1 Rising healthcare expenditure across emerging economies 53
5.2.3.2 Increasing number of hospitals 54
5.2.4 CHALLENGES 54
5.2.4.1 Rising adoption of refurbished tumor ablation systems 54
5.2.4.2 Hospital budget cuts 54
5.3 REGULATORY ANALYSIS 55
5.3.1 KEY REGULATORY BODIES AND GOVERNMENT AGENCIES 55
TABLE 1 NORTH AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 55
TABLE 2 EUROPE: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 55
TABLE 3 ASIA PACIFIC: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 56
TABLE 4 LATIN AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 57
TABLE 5 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 57
5.3.2 KEY REGULATORY GUIDELINES 57
5.3.2.1 US 57
TABLE 6 US FDA: MEDICAL DEVICE CLASSIFICATION 57
TABLE 7 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 58
FIGURE 21 PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES 58
5.3.2.2 Canada 58
TABLE 8 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 59
FIGURE 22 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES 59
5.3.2.3 Europe 60
FIGURE 23 EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES 61
5.3.2.4 Asia Pacific 61
5.3.2.4.1 Japan 61
TABLE 9 JAPAN: PMDA CLASSIFICATION OF ABLATION DEVICES 62
TABLE 10 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA) 62
5.3.2.4.2 China 62
TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES 63
5.3.2.4.3 India 64
TABLE 12 INDIA: CDSCO CLASSIFICATION OF ABLATION DEVICES 64
5.3.2.5 Latin America 64
5.3.2.5.1 Brazil 64
5.4 REIMBURSEMENT SCENARIO 65
TABLE 13 MEDICAL REIMBURSEMENT CPT CODES FOR MICROWAVE AND RADIOFREQUENCY ABLATION PROCEDURES IN US (EFFECTIVE JANUARY 1, 2022) 65
5.5 VALUE CHAIN ANALYSIS 66
5.5.1 RESEARCH & DEVELOPMENT 66
5.5.2 MANUFACTURING & ASSEMBLY 66
5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 67
FIGURE 24 TUMOR ABLATION MARKET: VALUE CHAIN ANALYSIS 67
5.6 SUPPLY CHAIN ANALYSIS 67
5.6.1 PROMINENT COMPANIES 67
5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES 67
5.6.3 END USERS 67
FIGURE 25 TUMOR ABLATION MARKET: SUPPLY CHAIN ANALYSIS 68
5.7 ECOSYSTEM ANALYSIS 68
FIGURE 26 TUMOR ABLATION MARKET: ECOSYSTEM ANALYSIS 68
TABLE 14 TUMOR ABLATION MARKET: ROLE IN ECOSYSTEM 69
5.8 INVESTMENT & FUNDING SCENARIO 69
FIGURE 27 NUMBER OF INVESTOR DEALS IN TUMOR ABLATION MARKET, BY KEY PLAYER, 2018–2022 69
FIGURE 28 VALUE OF INVESTOR DEALS IN TUMOR ABLATION MARKET, BY KEY PLAYER, 2018–2022 (USD MILLION) 70
5.9 PRICING ANALYSIS 70
FIGURE 29 AVERAGE SELLING PRICE TREND OF TUMOR ABLATION SYSTEMS, BY TECHNOLOGY 70
FIGURE 30 AVERAGE SELLING PRICE TREND OF TUMOR ABLATION SYSTEMS, BY REGION 71
TABLE 15 AVERAGE SELLING PRICE OF TUMOR ABLATION SYSTEMS, BY REGION, 2021–2023 71
5.10 TRADE ANALYSIS 72
TABLE 16 IMPORT DATA FOR TUMOR ABLATION SYSTEMS (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND) 72
TABLE 17 EXPORT DATA FOR TUMOR ABLATION SYSTEMS (HS CODE 9018), BY COUNTRY, 2018–2022 (USD THOUSAND) 72
5.11 PATENT ANALYSIS 73
FIGURE 31 PATENT DETAILS FOR TUMOR ABLATION MARKET (JANUARY 2013– DECEMBER 2023) 73
5.12 PORTER’S FIVE FORCE ANALYSIS 73
TABLE 18 PORTER’S FIVE FORCES ANALYSIS: TUMOR ABLATION MARKET 73
5.12.1 THREAT OF NEW ENTRANTS 74
5.12.2 THREAT OF SUBSTITUTES 74
5.12.3 BARGAINING POWER OF SUPPLIERS 74
5.12.4 BARGAINING POWER OF BUYERS 74
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 74
5.13 KEY CONFERENCES & EVENTS IN 2024–2025 75
TABLE 19 LIST OF MAJOR CONFERENCES & EVENTS IN TUMOR ABLATION MARKET, 2024–2025 75
5.14 CASE STUDY ANALYSIS 75
TABLE 20 CASE STUDY 1: RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY 75
TABLE 21 CASE STUDY 2: ABLATION OF LOCALIZED RENAL TUMOR 76
5.15 TECHNOLOGY ANALYSIS 76
5.15.1 KEY TECHNOLOGIES 76
5.15.1.1 Radiofrequency ablation and microwave ablation 76
5.15.1.2 Cryoablation 76
5.15.2 COMPLEMENTARY TECHNOLOGIES 76
5.15.2.1 Laparoscopy 76
5.15.2.2 Diagnostic imaging 77
5.15.3 ADJACENT TECHNOLOGIES 77
5.15.3.1 Electrosurgery 77
5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
FIGURE 32 REVENUE SHIFT IN TUMOR ABLATION MARKET 77
5.17 KEY STAKEHOLDERS & BUYING CRITERIA 78
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS 78
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE CATEGORIES 78
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%) 78
5.17.2 BUYING CRITERIA 79
FIGURE 34 KEY BUYING CRITERIA FOR PROCESS TUMOR ABLATION SYSTEMS 79
TABLE 23 KEY BUYING CRITERIA FOR TUMOR ABLATION SYSTEMS 79
5.18 UNMET NEEDS & KEY PAIN POINTS 79
TABLE 24 TUMOR ABLATION MARKET: CURRENT UNMET NEEDS 79
6 TUMOR ABLATION MARKET, BY TECHNOLOGY 80
6.1 INTRODUCTION 81
TABLE 25 TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 81
6.2 RADIOFREQUENCY ABLATION 81
6.2.1 LOW COST OF RADIOFREQUENCY ABLATION TO CONTRIBUTE TO MARKET GROWTH 81
TABLE 26 RADIOFREQUENCY ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION) 82
6.3 MICROWAVE ABLATION 82
6.3.1 ADVANTAGES OF MICROWAVE ABLATION TO BOOST MARKET GROWTH 82
TABLE 27 MICROWAVE ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION) 82
6.4 CRYOABLATION 83
6.4.1 HIGH SAFETY AND EFFICACY OF CRYOABLATION TO BOOST MARKET 83
TABLE 28 CRYOABLATION MARKET, BY REGION, 2022–2029 (USD MILLION) 83
6.5 HIGH-INTENSITY-FOCUSED ULTRASOUND (HIFU) 83
6.5.1 TECHNOLOGICAL ADVANCEMENTS IN ULTRASOUND ABLATION TO FAVOR MARKET GROWTH 83
TABLE 29 HIGH-INTENSITY-FOCUSED ULTRASOUND MARKET, BY REGION, 2022–2029 (USD MILLION) 84
6.6 OTHER TECHNOLOGIES 84
TABLE 30 OTHER TUMOR ABLATION TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION) 85
7 TUMOR ABLATION MARKET, BY PRODUCT TYPE 86
7.1 INTRODUCTION 87
TABLE 31 TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 87
TABLE 32 TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (UNITS) 87
7.2 GENERATORS 88
7.2.1 RISING ADOPTION OF TUMOR ABLATION SYSTEMS TO PROPEL MARKET GROWTH 88
TABLE 33 TUMOR ABLATION GENERATORS MARKET, BY REGION, 2022–2029 (USD MILLION) 88
7.3 PROBES/ELECTRODES 88
7.3.1 RADIOFREQUENCY ABLATION PROBES 88
7.3.1.1 Rising adoption of radiofrequency ablation systems for multiple applications to propel market growth 88
TABLE 34 RADIOFREQUENCY ABLATION PROBES MARKET, BY REGION, 2022–2029 (USD MILLION) 89
7.3.2 MICROWAVE ABLATION PROBES 89
7.3.2.1 Increasing cancer prevalence and precise ablation to boost adoption 89
TABLE 35 MICROWAVE ABLATION PROBES MARKET, BY REGION, 2022–2029 (USD MILLION) 89
7.3.3 OTHER PROBES/ELECTRODES 89
TABLE 36 OTHER TUMOR ABLATION PROBES/ELECTRODES MARKET, BY REGION, 2022–2029 (USD MILLION) 90
8 TUMOR ABLATION MARKET, BY MODE OF TREATMENT 91
8.1 INTRODUCTION 92
TABLE 37 TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION) 92
8.2 SURGICAL ABLATION 92
8.2.1 RISING UTILIZATION OF SURGICAL ABLATION IN END-USER FACILITIES TO PROPEL MARKET 92
TABLE 38 TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY REGION, 2022–2029 (USD MILLION) 93
8.3 LAPAROSCOPIC ABLATION 93
8.3.1 IMPROVED SUCCESS RATE AND REAL-TIME VISUALIZATION TO BOOST DEMAND 93
TABLE 39 TUMOR ABLATION MARKET FOR LAPAROSCOPIC ABLATION, BY REGION, 2022–2029 (USD MILLION) 94
8.4 PERCUTANEOUS ABLATION 94
8.4.1 SHORTER RECOVERY TIME AND COST-EFFECTIVENESS OF PROCEDURE TO DRIVE SEGMENT 94
TABLE 40 TUMOR ABLATION MARKET FOR PERCUTANEOUS ABLATION, BY REGION, 2022–2029 (USD MILLION) 95
9 TUMOR ABLATION MARKET, BY APPLICATION 96
9.1 INTRODUCTION 97
TABLE 41 TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 97
9.2 LIVER CANCER 97
9.2.1 PROMISING OUTCOMES OF ABLATION IN TREATING HCC TO DRIVE MARKET 97
TABLE 42 TUMOR ABLATION MARKET FOR LIVER CANCER, BY REGION, 2022–2029 (USD MILLION) 98
9.3 LUNG CANCER 98
9.3.1 RISING INCIDENCE OF LUNG CANCER TO FUEL MARKET 98
TABLE 43 TUMOR ABLATION MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION) 98
9.4 KIDNEY CANCER 99
9.4.1 RISING PREVALENCE OF KIDNEY CANCER AND MINIMAL DAMAGE OF HEALTHY TISSUE TO DRIVE ADOPTION 99
TABLE 44 TUMOR ABLATION MARKET FOR KIDNEY CANCER, BY REGION, 2022–2029 (USD MILLION) 99
9.5 BONE CANCER 99
9.5.1 RISING USE OF ABLATION TECHNIQUES TO TREAT OSTEOID OSTEOMA TO BOOST GROWTH 99
TABLE 45 TUMOR ABLATION MARKET FOR BONE CANCER, BY REGION, 2022–2029 (USD MILLION) 100
9.6 OTHER APPLICATIONS 100
TABLE 46 TUMOR ABLATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 100
10 TUMOR ABLATION MARKET, BY END USER 101
10.1 INTRODUCTION 102
TABLE 47 TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION) 102
10.2 HOSPITALS & CLINICS 102
10.2.1 INCREASING ADOPTION OF ADVANCED TUMOR ABLATION SYSTEMS TO PROPEL MARKET 102
TABLE 48 TUMOR ABLATION MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION) 103
10.3 CANCER CARE CENTERS 103
10.3.1 GROWING ESTABLISHMENT OF CANCER CARE CENTERS TO FUEL MARKET 103
TABLE 49 TUMOR ABLATION MARKET FOR CANCER CARE CENTERS, BY REGION, 2022–2029 (USD MILLION) 103
10.4 OTHER END USERS 104
TABLE 50 TUMOR ABLATION MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION) 104
11 TUMOR ABLATION MARKET, BY REGION 105
11.1 INTRODUCTION 106
TABLE 51 TUMOR ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION) 106
11.2 NORTH AMERICA 106
FIGURE 35 NORTH AMERICA: TUMOR ABLATION MARKET SNAPSHOT 107
TABLE 52 NORTH AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 53 NORTH AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 108
TABLE 54 NORTH AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 108
TABLE 55 NORTH AMERICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION) 108
TABLE 56 NORTH AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 109
TABLE 57 NORTH AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION) 109
11.2.1 NORTH AMERICA: RECESSION IMPACT 109
11.2.2 US 110
11.2.2.1 Rising prevalence of cancer to propel market growth 110
TABLE 58 US: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 110
11.2.3 CANADA 110
11.2.3.1 Growing burden of cancer to support market growth 110
TABLE 59 CANADA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 111
11.3 EUROPE 111
TABLE 60 EUROPE: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 61 EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 112
TABLE 62 EUROPE: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 112
TABLE 63 EUROPE: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION) 112
TABLE 64 EUROPE: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 113
TABLE 65 EUROPE: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION) 113
11.3.1 EUROPE: RECESSION IMPACT 113
11.3.2 GERMANY 114
11.3.2.1 Highly developed healthcare infrastructure and rising disease incidence to ensure strong growth prospects 114
TABLE 66 GERMANY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 114
11.3.3 FRANCE 114
11.3.3.1 Growing geriatric population to support market growth in France 114
TABLE 67 FRANCE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 115
11.3.4 UK 115
11.3.4.1 Growing target patient population to support market growth in UK 115
TABLE 68 UK: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 115
11.3.5 ITALY 116
11.3.5.1 Rising awareness to support market growth 116
TABLE 69 ITALY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 116
11.3.6 SPAIN 116
11.3.6.1 Increasing government funding for research to support market growth 116
TABLE 70 SPAIN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 117
11.3.7 REST OF EUROPE 117
TABLE 71 REST OF EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 117
11.4 ASIA PACIFIC 118
FIGURE 36 ASIA PACIFIC: TUMOR ABLATION MARKET SNAPSHOT 118
TABLE 72 ASIA PACIFIC: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 73 ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 119
TABLE 74 ASIA PACIFIC: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 119
TABLE 75 ASIA PACIFIC: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION) 120
TABLE 76 ASIA PACIFIC: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 120
TABLE 77 ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION) 120
11.4.1 ASIA PACIFIC: RECESSION IMPACT 121
11.4.2 JAPAN 121
11.4.2.1 Presence of universal healthcare reimbursement scenario to drive market growth 121
TABLE 78 JAPAN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 122
11.4.3 CHINA 122
11.4.3.1 Increasing patient pool and government initiatives for healthcare development to fuel market growth 122
TABLE 79 CHINA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 122
11.4.4 INDIA 123
11.4.4.1 Ongoing modernization and infrastructure development in India to support market growth 123
TABLE 80 INDIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 123
11.4.5 AUSTRALIA 123
11.4.5.1 Rising research investments and awareness campaigns to support market growth 123
TABLE 81 AUSTRALIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 124
11.4.6 SOUTH KOREA 124
11.4.6.1 Rising R&D and promising clinical trials to positively impact market growth 124
TABLE 82 SOUTH KOREA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 124
11.4.7 REST OF ASIA PACIFIC 124
TABLE 83 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 125
11.5 LATIN AMERICA 125
11.5.1 LATIN AMERICA: RECESSION IMPACT 125
TABLE 84 LATIN AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 85 LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 126
TABLE 86 LATIN AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 126
TABLE 87 LATIN AMERICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION) 127
TABLE 88 LATIN AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 127
TABLE 89 LATIN AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION) 127
11.5.2 BRAZIL 128
11.5.2.1 Modernization of healthcare facilities in Brazil to boost market 128
TABLE 90 BRAZIL: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 128
11.5.3 MEXICO 129
11.5.3.1 Availability of advanced care and increasing awareness programs to fuel market growth in Mexico 129
TABLE 91 MEXICO: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 129
11.5.4 REST OF LATIN AMERICA 129
TABLE 92 REST OF LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 130
11.6 MIDDLE EAST & AFRICA 130
11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH 130
TABLE 93 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 131
TABLE 94 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 131
TABLE 95 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION) 131
TABLE 96 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 132
TABLE 97 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION) 132
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 132
12 COMPETITIVE LANDSCAPE 133
12.1 OVERVIEW 133
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 133
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN TUMOR ABLATION MARKET 133
TABLE 98 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES 133
12.3 REVENUE ANALYSIS 134
FIGURE 37 REVENUE ANALYSIS OF TOP THREE PLAYERS IN TUMOR ABLATION MARKET (2021–2023) 134
12.4 MARKET SHARE ANALYSIS 135
FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023) 135
TABLE 99 TUMOR ABLATION TECHNOLOGY MARKET: DEGREE OF COMPETITION 135
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 136
12.5.1 STARS 136
12.5.2 EMERGING LEADERS 137
12.5.3 PERVASIVE PLAYERS 137
12.5.4 PARTICIPANTS 137
FIGURE 39 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 137
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 138
12.5.5.1 Company footprint 138
FIGURE 40 TUMOR ABLATION MARKET: COMPANY FOOTPRINT 138
12.5.5.2 Technology footprint 138
TABLE 100 TUMOR ABLATION MARKET: TECHNOLOGY FOOTPRINT 138
12.5.5.3 Region footprint 139
TABLE 101 TUMOR ABLATION MARKET: REGION FOOTPRINT 139
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 140
12.6.1 PROGRESSIVE COMPANIES 140
12.6.2 RESPONSIVE COMPANIES 140
12.6.3 DYNAMIC COMPANIES 140
12.6.4 STARTING BLOCKS 140
FIGURE 41 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 141
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 141
TABLE 102 TUMOR ABLATION MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 141
TABLE 103 TUMOR ABLATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 142
12.7 COMPANY VALUATION & FINANCIAL METRICS 143
12.7.1 FINANCIAL METRICS 143
FIGURE 42 EV/EBITDA OF KEY VENDORS 143
12.7.2 COMPANY VALUATION 143
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 143
12.8 BRAND/PRODUCT COMPARISON 144
FIGURE 44 BRAND/PRODUCT COMPARATIVE ANALYSIS 144
12.9 COMPETITIVE SCENARIO 144
12.9.1 PRODUCT LAUNCHES/APPROVALS 144
TABLE 104 TUMOR ABLATION MARKET: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2024 144
12.9.2 DEALS 145
TABLE 105 TUMOR ABLATION MARKET: DEALS, JANUARY 2021–MARCH 2024 145
12.9.3 EXPANSIONS 147
TABLE 106 TUMOR ABLATION MARKET: EXPANSIONS, JANUARY 2021–MARCH 2024 147
13 COMPANY PROFILES 148
13.1 KEY PLAYERS 148
(Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats)*
13.1.1 MEDTRONIC PLC 148
TABLE 107 MEDTRONIC PLC: COMPANY OVERVIEW 148
FIGURE 45 MEDTRONIC PLC: COMPANY SNAPSHOT (2023) 149
TABLE 108 MEDTRONIC PLC: PRODUCTS OFFERED 149
TABLE 109 MEDTRONIC PLC: PRODUCT APPROVALS 150
13.1.2 JOHNSON & JOHNSON MEDTECH (ETHICON) 151
TABLE 110 JOHNSON & JOHNSON MEDTECH: COMPANY OVERVIEW 151
FIGURE 46 JOHNSON & JOHNSON MEDTECH: COMPANY SNAPSHOT (2022) 151
TABLE 111 JOHNSON & JOHNSON MEDTECH: PRODUCTS OFFERED 152
13.1.3 STRYKER CORPORATION 153
TABLE 112 STRYKER CORPORATION: COMPANY OVERVIEW 153
FIGURE 47 STRYKER CORPORATION: COMPANY SNAPSHOT (2023) 154
TABLE 113 STRYKER CORPORATION: PRODUCTS OFFERED 154
TABLE 114 STRYKER CORPORATION: PRODUCT APPROVALS 155
TABLE 115 STRYKER CORPORATION: EXPANSIONS 155
13.1.4 VARIAN MEDICAL SYSTEMS, INC. 156
TABLE 116 VARIAN MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW 156
FIGURE 48 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2023) 157
TABLE 117 VARIAN MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED 157
TABLE 118 VARIAN MEDICAL SYSTEMS, INC.: PRODUCT LAUNCHES 158
TABLE 119 VARIAN MEDICAL SYSTEMS, INC.: DEALS 158
13.1.5 ANGIODYNAMICS, INC. 160
TABLE 120 ANGIODYNAMICS, INC.: COMPANY OVERVIEW 160
FIGURE 49 ANGIODYNAMICS, INC.: COMPANY SNAPSHOT (2023) 161
TABLE 121 ANGIODYNAMICS, INC.: PRODUCTS OFFERED 161
TABLE 122 ANGIODYNAMICS, INC.: DEALS 162
13.1.6 BOSTON SCIENTIFIC CORPORATION 163
TABLE 123 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 163
FIGURE 50 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023) 164
TABLE 124 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 164
13.1.7 EDAP TMS S.A. 165
TABLE 125 EDAP TMS S.A.: COMPANY OVERVIEW 165
FIGURE 51 EDAP TMS S.A.: COMPANY SNAPSHOT (2023) 165
TABLE 126 EDAP TMS S.A.: PRODUCTS OFFERED 166
13.1.8 MERMAID MEDICAL 167
TABLE 127 MERMAID MEDICAL: COMPANY OVERVIEW 167
TABLE 128 MERMAID MEDICAL: PRODUCTS OFFERED 167
13.1.9 CANYON MEDICAL INC. 168
TABLE 129 CANYON MEDICAL INC.: COMPANY OVERVIEW 168
TABLE 130 CANYON MEDICAL INC.: PRODUCTS OFFERED 168
13.1.10 OLYMPUS CORPORATION 169
TABLE 131 OLYMPUS CORPORATION: COMPANY OVERVIEW 169
FIGURE 52 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2023) 170
TABLE 132 OLYMPUS CORPORATION: PRODUCTS OFFERED 170
TABLE 133 OLYMPUS CORPORATION: PRODUCT LAUNCHES 171
13.1.11 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD. 172
TABLE 134 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 172
TABLE 135 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.: PRODUCTS OFFERED 172
13.1.12 MERIT MEDICAL SYSTEMS, INC. 173
TABLE 136 MERIT MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW 173
FIGURE 53 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022) 174
TABLE 137 MERIT MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED 174
13.1.13 BIOVENTUS INC. 175
TABLE 138 BIOVENTUS INC.: COMPANY OVERVIEW 175
FIGURE 54 BIOVENTUS INC.: COMPANY SNAPSHOT (2023) 176
TABLE 139 BIOVENTUS INC.: PRODUCTS OFFERED 176
TABLE 140 BIOVENTUS INC.: DEALS 177
13.1.14 ICECURE MEDICAL LTD. 178
TABLE 141 ICECURE MEDICAL LTD.: COMPANY OVERVIEW 178
FIGURE 55 ICECURE MEDICAL LTD.: COMPANY SNAPSHOT (2023) 179
TABLE 142 ICECURE MEDICAL LTD.: PRODUCTS OFFERED 179
TABLE 143 ICECURE MEDICAL LTD.: PRODUCT APPROVALS 180
TABLE 144 ICECURE MEDICAL LTD.: DEALS 180
13.1.15 CONMED CORPORATION 182
TABLE 145 CONMED CORPORATION: COMPANY OVERVIEW 182
FIGURE 56 CONMED CORPORATION: COMPANY SNAPSHOT (2023) 182
TABLE 146 CONMED CORPORATION: PRODUCTS OFFERED 183
13.2 OTHER PLAYERS 184
13.2.1 MONTERIS MEDICAL 184
13.2.2 MIANYANG SONIC ELECTRONIC 184
13.2.3 RF MEDICAL 185
13.2.4 MINIMAX MEDICAL HOLDING GROUP 185
13.2.5 SONABLATE 186
13.2.6 ECO MEDICAL TECHNOLOGY (NANJING) CO., LTD. 186
13.2.7 STARMED CO., LTD. 187
13.2.8 SURGNOVA 188
13.2.9 CREO MEDICAL 189
13.2.10 MEDSPHERE SHANGHAI 189
*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
14 APPENDIX 190
14.1 DISCUSSION GUIDE 190
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 194
14.3 CUSTOMIZATION OPTIONS 196
14.4 RELATED REPORTS 196
14.5 AUTHOR DETAILS 197
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価判定を受けているインドに本社をおく市場調査会社です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD10,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- ご注文後2営業日以内
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
割引可能なレポートが多数ございます。価格・サンプルについてはお気軽にご相談ください。
最新調査レポート
- CAR-T細胞療法市場 – 2029年までの世界予測 2024-07-22
- ストーンフローリング市場 – 2029年までの世界予測 2024-07-19
- グリーンメタノール市場 – 2030年までの世界予測 2024-07-19
- テトラアセチルエチレンジアミン (TAED) 市場 – 2029年までの世界予測 2024-07-18
- バッテリーTIC（試験・検査・認証）市場 – 2029年までの世界予測 2024-07-18